- Home
- MYGN vs CNMD Comparison
MYGN vs CNMD Comparison
Compare MYGN & CNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- CNMD
- Stock Information
- Founded
- MYGN 1991
- CNMD 1970
- Country
- MYGN United States
- CNMD United States
- Employees
- MYGN N/A
- CNMD N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CNMD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- MYGN Health Care
- CNMD Health Care
- Exchange
- MYGN Nasdaq
- CNMD Nasdaq
- Market Cap
- MYGN 744.7M
- CNMD 1.7B
- IPO Year
- MYGN 1995
- CNMD 1987
- Fundamental
- Price
- MYGN $5.60
- CNMD $54.33
- Analyst Decision
- MYGN Hold
- CNMD Hold
- Analyst Count
- MYGN 15
- CNMD 5
- Target Price
- MYGN $15.14
- CNMD $62.20
- AVG Volume (30 Days)
- MYGN 1.6M
- CNMD 418.9K
- Earning Date
- MYGN 08-05-2025
- CNMD 07-30-2025
- Dividend Yield
- MYGN N/A
- CNMD 1.47%
- EPS Growth
- MYGN N/A
- CNMD 46.38
- EPS
- MYGN N/A
- CNMD 3.81
- Revenue
- MYGN $831,300,000.00
- CNMD $1,315,998,000.00
- Revenue This Year
- MYGN N/A
- CNMD $6.27
- Revenue Next Year
- MYGN $6.68
- CNMD $5.62
- P/E Ratio
- MYGN N/A
- CNMD $14.26
- Revenue Growth
- MYGN 7.38
- CNMD 4.32
- 52 Week Low
- MYGN $3.81
- CNMD $46.00
- 52 Week High
- MYGN $29.30
- CNMD $78.19
- Technical
- Relative Strength Index (RSI)
- MYGN 59.81
- CNMD 49.86
- Support Level
- MYGN $4.90
- CNMD $51.43
- Resistance Level
- MYGN $5.74
- CNMD $55.19
- Average True Range (ATR)
- MYGN 0.27
- CNMD 1.55
- MACD
- MYGN 0.10
- CNMD 0.18
- Stochastic Oscillator
- MYGN 85.71
- CNMD 76.74
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About CNMD CONMED Corporation
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The firm currently reports through two reporting units, orthopedic surgery, and general surgery. From a geographic perspective, the firm is U.S.-centric, with maximum domestic sales accounting for revenue, EMEA accounting for second place, APAC at third, and the non-U.S. Americas region driving the remaining revenue.